In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model a pre-clinical study
In vitro target validation and in vivo ef cacy of p38 MAP kinase inhibition in established chronic collagen-induced
arthritis model: a pre-clinical study
K. Triantaphyllopoulos1,2, L. Madden1, I. Rioja3, D. Essex1, J. Buckton3,
R. Malhotra3, K. Ray3, M. Binks3, E.M. Paleolog1
Kennedy Institute of Rheumatology, and 2Faculty of Medicine, National Heart and Lung Institute, Imperial College London, United Kingdom; 3GSK Medicines Research Centre, Stevenage, United Kingdom.
1
Objective
The aim of the present study was to determine the in vivo ef cacy of p38 mitogen-activated protein kinase (MAPK)
inhibitors, namely GW856553X and GSK678361, in murine models of arthritis.Methods
The effect of p38 MAPK inhibitors was tested in 2 variants of the collagen-induced arthritis model (CIA) in DBA/1 mice, acute arthritis induced by heterologous collagen and chronic relapsing arthritis induced by homologous collagen. Animals were treated after onset of arthritis. Furthermore, post-onset disease ef cacy of GSK678361 was tested in the chronic model, so as to determine the effects on established arthritis. In vitro studies were carried out with GW856553X, using
human umbilical vein endothelial cells, to determine potential effects of GW856553X on the vasculature.
Results
In both acute and chronic arthritis, GW856553X reduced signs and symptoms of disease, and protected joints from damage. The effect of GW856553X in chronic CIA was con rmed using an alternative compound, GSK678361. Importantly, treatment with GSK678361 from 14 days post-onset of chronic arthritis completely reversed signs of established disease and joint destruction. Mechanism of action studies demonstrated that GW856553X inhibited endothelial cell migration and angiogenesis in vitro, with reduced pro-in ammatory cytokine production.Conclusions
Suppression of murine CIA by the p38 MAPK inhibitors GW856553X and GSK678361 suggests that they may have
therapeutic potential for future use in RA if safe clinical dosing achieves adequate compound exposure.
Key words
Arthritis, mouse, p38 MAP kinase, cytokine, joint.
p38 inhibition and not MK2 inhibition enhances ...efficacy in in vitro and in vivo inflammatory ... Novel inhibitor of p38 MAP kinase as an anti...
(2013) In Vitro and In Vivo Experimental Models...Efficacy of Antineoplastic Drugs on Urinary Bladder...inhibition are the oldest and most commonly used ...
The potent anti-leukemia efficacy of Icaritin in murine model demonstrated ... Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a...
of 4T1 breast cancer in vitro and in vivo. ...In vivo growth-inhibition of Sarcoma 180 by ...Chemopreventive efficacy of curcumin and piperine ...
namely stimulation of osteoblastic cell proliferation and inhibition of ...In summary, the present study clearly demonstrates the in vivo efficacy of ...
Experimental models of elevated Pgc in vivo ...In vitro mechanical stimulation therefore represents ...of p38 MAP kinase and subsequent inhibition by ...
Target validation Seattle/Chicago: Structure ...(in vitro systems) Biochemical (kinase, protease,...Inhibition Slide 20 deCODE Capabilities: In Vivo ...
In vitro models (enzyme inhibition, receptor ...and in silico) Bottleneck: Target validation, “... www.kubinyi.de MAP Kinase Pathways Kinases www....
[1] Target: p38 MAPK in vitro: In SHR-SPs receiving a salt-fat diet...Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, ...
Efficacy of a Tyrosine... 暂无评价 9页 免费 ...in vitro screening for tyrosine kinase inhibitors ...Also, there is substantial in vivo inhibition of...
热门文档